SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis

SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis

IntroductionSGLT2 inhibitors (SGLT2Is) have demonstrated cardioprotective and nephroprotective effects in patients with and without diabetes. Recent studies suggest that SGLT2Is may reduce the risk of contrast-induced nephropathy (CIN) in patients with diabetes undergoing coronary arteriography (CAG...

Full description

Bibliographic Details
Main Authors:	Edinson Dante Meregildo-Rodriguez, Martha Genara Asmat-Rubio, Gustavo Adolfo Vásquez-Tirado
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Endocrinology
Subjects:	sodium-glucose transporter 2 inhibitors SGLT2 inhibitors acute kidney injury contrast-induced nephropathy systematic review meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1307715/full

Similar Items

The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study
by: Mateus Paiva Marques Feitosa, et al.
Published: (2023-06-01)

Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis
by: Rui Hua, et al.
Published: (2022-06-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
by: Hideyuki Okuma, et al.
Published: (2021-07-01)

Diabetic nephropathy: newer therapeutic perspectives
by: Krishna C. Keri, et al.
Published: (2018-07-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction
by: Uğur Özkan, et al.
Published: (2023-03-01)

Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy
by: Anuj Kumar Borah, et al.
Published: (2022-05-01)

A Transcriptome Array-Based Approach to Link SGLT-2 and Intrarenal Complement C5 Synthesis in Diabetic Nephropathy
by: Peter Korsten, et al.
Published: (2023-12-01)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021-07-01)

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy
by: Archit Dhaiya; Rajeev Sharma; Nagendra Bhoopathy; Rajeev Agarwal
Published: (2023-07-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
by: Peyman Bidram, et al.
Published: (2015-01-01)

Efficacy of SGLT2 inhibitors in IgA nephropathy associated with alcoholic liver cirrhosis accompanied by nephrotic syndrome: a case report
by: Yusuke Yoshimura, et al.
Published: (2024-01-01)

SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
by: Canan Ersoy
Published: (2020-01-01)

A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery
by: Deborah A. Osafehinti, MD, et al.
Published: (2021-01-01)

Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
by: Koichiro Kajiwara, et al.
Published: (2021-08-01)

Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life
by: Ramón Baeza-Trinidad, et al.
Published: (2023-07-01)

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
by: Dimitrios Patoulias
Published: (2018-04-01)

Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
by: Samuel Seidu, et al.
Published: (2022-01-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

IgA nephropathy: a review of existing and emerging therapies
by: Sahibzadi Mahrukh Noor, et al.
Published: (2023-05-01)

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
by: Masa-Ki Inoue, et al.
Published: (2019-07-01)

Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
by: Piotr Londzin, et al.
Published: (2022-11-01)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
by: Chiara Maria Assunta Cefalo, et al.
Published: (2019-02-01)

Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach
by: JÉSSICA B. DE JESUS, et al.
Published: (2022-10-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

Impact of 719Trp>Arg Polymorphism of KIF 6 Gene on Contrast Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention
by: Lucia Barbieri, et al.
Published: (2022-02-01)

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
by: Lucia Scisciola, et al.
Published: (2022-09-01)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
by: Yan-Ting Lu, et al.
Published: (2018-11-01)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
by: Lubin Xu, et al.
Published: (2017-06-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
by: Ewald Kolesnik, et al.
Published: (2022-01-01)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)

Prophylactic Effect of Theophylline in Renal Contrast Nephropathy after Coronary Angiography
by: Mokhberi Vahid, et al.
Published: (2006-04-01)

Prophylactic Effect of Theophylline in Renal Contrast Nephropathy after Coronary Angiography
by: Asadollah Mohseni, et al.
Published: (2006-07-01)

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
by: Pei-Chien Tsai, et al.
Published: (2023-03-01)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
by: Hang-Long Li, et al.
Published: (2021-05-01)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023-11-01)